Armistice Capital, LLC Reports New 9.22% Stake in Ironwood Pharmaceuticals, Inc. (IRWD)

Armistice Capital, LLC and its managing member, Steven Boyd, have filed a Schedule 13G/A reporting a significant increase in their position in Ironwood Pharmaceuticals, Inc. (IRWD). As of the event date on March 31, 2026, the reporting persons beneficially own 15,028,000 shares of Class A common stock, representing a 9.22% ownership stake in the company. This is a substantial increase from the previously reported 0.0% ownership, indicating a new major position or a significant re-entry into the stock. The shares are held directly by the Armistice Capital Master Fund Ltd., for which Armistice Capital, LLC serves as the investment manager. Steven Boyd, as managing member, shared voting and dispositive power over these shares. The filing was made under Rule 13d-1(b), certifying that the securities were acquired in the ordinary course of business and not for the purpose of influencing or changing the control of the issuer. This filing marks the sixth amendment to their Schedule 13G for this issuer.